Literature DB >> 558224

Heterogeneity of circulating C-peptide.

H Kuzuya, P M Blix, D L Horwitz, A H Rubenstein, D F Steiner, C Binder, O K Faber.   

Abstract

Serum C-peptide levels vary when measured with different immunoassay systems. In order to assess the factors contributing to this finding, serum C-peptide was measured in two assays utilizing different antisera, but the same standards and labeled peptide. The antisera were characterized with synthetic C-peptide fragments and their reactivities towards some of these fragments differed. The results of dilution and recovery tests and stability of the C-peptide during storage showed differences between the two assays. Gel filtration experiments indicated heterogeneity within the major C-peptide peak, and, in addition, a smaller peak of lower molecular weight material was present in some sera. Although degradation of serum C-peptide may occur during storage or with freezing and thawing, fragments of C-peptide may also be secreted or arise during in vivo metabolism.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 558224     DOI: 10.1210/jcem-44-5-952

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  8 in total

1.  Prevalence of residual B cell function and its metabolic consequences in Type 1 (insulin-dependent) diabetes.

Authors:  S Madsbad
Journal:  Diabetologia       Date:  1983-03       Impact factor: 10.122

Review 2.  The expanding clinical use of C-peptide radioimmunoassay.

Authors:  M Rendell
Journal:  Acta Diabetol Lat       Date:  1983 Apr-Jun

3.  Use of a common standard for comparison of insulin C-peptide measurements by different laboratories.

Authors:  C P Caygill; R E Gaines Das; D R Bangham
Journal:  Diabetologia       Date:  1980-03       Impact factor: 10.122

4.  Familial hyperproinsulinemia: partial characterization of circulating proinsulin-like material.

Authors:  K H Gabbay; R M Bergenstal; J Wolff; M E Mako; A H Rubenstein
Journal:  Proc Natl Acad Sci U S A       Date:  1979-06       Impact factor: 11.205

5.  Kinetics of human connecting peptide in normal and diabetic subjects.

Authors:  O K Faber; C Hagen; C Binder; J Markussen; V K Naithani; P M Blix; H Kuzuya; D L Horwitz; A H Rubenstein; N Rossing
Journal:  J Clin Invest       Date:  1978-07       Impact factor: 14.808

6.  Characterization of proinsulin-insulin intermediates in human plasma.

Authors:  C de Haën; S A Little; J M May; R H Williams
Journal:  J Clin Invest       Date:  1978-10       Impact factor: 14.808

7.  Hyperinsulinism after removal of a pheochromocytoma.

Authors:  C Reynolds; G E Wilkins; N Schmidt; W A Doll; P M Blix
Journal:  Can Med Assoc J       Date:  1983-08-15       Impact factor: 8.262

8.  Use of a glucose controlled insulin infusion system (artificial beta cell) to control diabetes during surgery.

Authors:  S S Schwartz; D L Horwitz; B Zehfus; B Langer; A R Moossa; G Ribeiro; E Kaplan; A H Rubenstein
Journal:  Diabetologia       Date:  1979-03       Impact factor: 10.122

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.